Device Trial Radar · NCT07045194
Virtue® SAB in the Treatment of Coronary ISR Trial
Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
740
Planned (sponsor's estimate)
Start
Oct 20, 2025
Primary completion
Oct 2028
Study completion Oct 2032
Sponsor
- Lead sponsor
- Orchestra BioMed, IncNot on our public-company list
- Sponsor type
- Industry
- First posted
- Jul 1, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A prospective, multi-center, single-blind, randomized (1:1), non-inferiority study comparing clinical outcomes of the Virtue® Sirolimus AngioInfusion™ Balloon (SAB) to the AGENT™ Paclitaxel Drug-Coated Balloon (DCB) in the treatment of coronary artery in-stent restenosis (ISR).
Conditions
- Coronary Artery Disease
Interventions
Virtue Sirolimus AngioInfusion BalloonDevice
Percutaneous Coronary Intervention
AGENT™ Paclitaxel Drug-Coated BalloonDevice
Percutaneous Coronary Intervention
Primary outcomes
What the sponsor says the trial is designed to measure.
- Target Lesion Failure (TLF) at 12 monthsTime frame: 12 months
Locations
22 sites in 1 country. Site status is shown where the registry gives one.
Banner University Medical Center Phoenix
Phoenix, Arizona · Recruiting
The Cardiac and Vascular Institute
Gainesville, Florida · Recruiting
Memorial Regional Hospital
Hollywood, Florida · Recruiting
19 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.